Stephen Goutman, MD
Neurology · Ann Arbor, MINPI 1740455161
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,779 of the $10,709 with a category attached, or 91.3%. Every reported general payment came from a single manufacturer, Biogen. Reporting peaked in 2019 at $7,267 and has fallen 95.4% since, to $338 in 2024.
Across 14 payments — averaging $764.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$11K
Across 27 payments — averaging $9272.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orion Corporation$194K
- Mitsubishi Tanabe Pharma Development America, Inc.$37K
- UCB SA$10K
- Biohaven Pharmaceutical Holding Company Ltd.$9K
What the payments were for
- Consulting fees$9,77991%
- Travel & lodging$2572%
- Food & beverage$6736%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 14 | $10,709 |
How this compares
$10,709 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 110 | $1,557,622 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 21 | $275,286 |
| Riluzole | 115 | $23,309 |
| Baclofen | 67 | $3,116 |
| Atropine Sulfate | 25 | $1,752 |
| Duloxetine Hcl | 19 | $689 |
| Gabapentin | 16 | $442 |
| Mirtazapine | 12 | $280 |
| Levetiracetam | 14 | $146 |
| Buspirone Hcl | 17 | $93 |
Paid to pharmacies, not to this prescriber.
Other neurology in Ann Arbor
- Wade CooperAnn Arbor$991K
- James WeintraubAnn Arbor$194K
- Maysa HamadeAnn Arbor$90K
- Kelvin ChouAnn Arbor$52K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.